First report of OXA-143-lactamase producing Acinetobacter baumannii inQom


1 Department of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran

2 Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran


Objective(s):Antibiotic resistance in Acinetobacter baumannii and outbreaks caused by this organism have been reported from several areas of the world. The present study aimed at determining the antibiotic susceptibility profiles and the distribution of OXA-type beta-lactamases among Iranian Acinetobacter baumannii isolates from Qom of Iran.
Materials and Methods: For this study, 108 non-duplicate A. baumannii isolates were obtained from clinical specimens in four teaching hospitals in Qom in the central of Iran. The antimicrobial susceptibility of isolates was tested by standard disk diffusion and prevalence of bla OXA genes was investigated by PCR method.
Results: Among 97 carbapenem non-susceptible isolates of A. baumannii, 90.72% (88 isolates) isolates showed extensive drug resistance to multiple antibiotics. Among carbapenem resistant isolates, 100% carried blaOXA-51-like, 82.47% carried blaOXA-23-like, 55.67% carried blaOXA-58-like, 22.68% carried blaOXA-40-like and 14.43% had blaOXA-143-like resistance genes.
Conclusion: This study demonstrated high genetic diversity of OXA genes among isolates of A. baumannii in Qom, Iran.


1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-582.

2. Moradi J, Hashemi B, Bahador A. Antibiotic resistance of Acinetobacter baumannii in Iran: A systemic review of the published literature. Osong Public Health Res Perspect 2015; 6:79-86.

3. Sadeghi P, Khosravi A, Hashemi A, Beiranvand M. Identification of clinical isolates of Acinetobacter baumannii from Iran and study of their heterogeneity. J Chin Med Assoc 2016; 79:382-386.

4. Magiorakos AP, Srinivassan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-281.

5. Helfand MS, Bonomo RA. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens. Curr Opin Pharmacol 2005; 5:452-458.

6.  Farajnia S, Azhari F, Alikhani MY, Hosseini MK, Peymani A, Sohrabi N. Prevalence of PER and VEB type extended spectrum betalactamases among multidrug resistant Acinetobacter baumannii isolates in North-West of Iran. Iran J Basic Med Sci 2013; 16:751-755.

7. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanism and epidemiology. Clin Microbiol Infect 2006; 12:826-836.

8. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a novel carbapenem-hydroltoyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2009; 53:5035-5038.

9. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65:233-238.

10. Walther-Rasmussen J, Hoiby N. OXA-type carbapenemases. J Antimicrob Chemother 2006; 57:373-383.

11. Paton R, Miles RS, Hood J, Amyes SGB. ARI-1: Beta lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 1993; 2:81-88.

12. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 2000; 44:196-199.

13. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23-like carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 2010; 16:35-40.

14. Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000; 44:1556-1561.

15. Evans BA, Hamouda A, Towner KJ, Amyes SG. OXA-51-like beta-lactamases and their association with particular epidemic lineages of Acinetobacter baumannii. Clin Microbiol Infect 2008; 14:268-275.

16. Poirel L, Marque S, Heritier C, Segonds C, Chabanon G, Nordmann P. OXA-58, a novel class D beta-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49:202-208.

17. Bergogne-Berezin E, Towner KJ. Acinetobacter spp as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1993; 9:148-165.

18. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 2006; 44:2974-2976.

19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests.11th ed. Approved standards, CLSI Document M02-A11, Wayne, PA: 2012.

20. Pitout JD, Gregson DB, Poirl L, McClure JA, Le P, Church DL. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43:3129-3135.

21. Zhou H, Pi BR, Yang Q, Yu YS, Chen YG, Li LJ, et al. Dissemination of imipenem resistant Acinetobacter baumannii strains carrying the ISAba1 bla OXA-23 genes in a Chinese hospital. J Med Microbiol 2007; 56:1076-1080.

22. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006; 27:351-353.

23. Ruiz M,  Marti S, Fernandez-Cuenca F, Pascual A, Vila J. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin Microbiol Infect 2007; 13:1192-1198.

24. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Perez-Paredes C, Barrero-Almodovar AE, et al. Risk factors for Acinetobacter baumannii bacteremia in critically III patients: A cohort study. Clin Infect Dis 2001; 33:939-946.

25. Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of bla OXA genes among Acinetobacter spp. isolated from patients at Tehran hospitals. Jpn J Infect Dis 2008; 61:274-278.

26. Papa A, Koulourida V, Souliou E. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in a newly established Greek hospital. Microb Drug Resist 2009; 15:257-260.

27. Rahbar M, Monnavar KM, Vatan KK, Fadaei-haq A, Shakerian F. Carbapenem resistance in gram negative bacilli isolates in an Iranian 1000-bed Tertiary hospital. Pak J Med Sci 2008; 24:537-540.

28. Sohrabi N, Farajnia S, Akhi MT, Nahaei MR, Naghili B, Peymani A, et al . Prevalence of OXA-type beta-lactamases among Acinetobacter baumannii isolates from Northwest of Iran. Microb Drug Resist 2012; 18:385-389.

29. Gur D, Korten V, Unal S, Deshpande LM, Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58) producing Acinetobacter baumannii: report from the Turkish Sentry Program Site. J Med Microbiol 2008; 57:1529-1532.

30. Stoeva T, Higgins PG, Savov E, Markovska R, Mitov I, Seifert H. Nosocomial spread of OXA-23 and OXA-58 beta-lactamase producing Acinetobacter baumannii in a Bulgarian hospital. J Antimicrob Chemother 2009; 63:618-620.

31. Japoni-Nejad A, Sofian M, VanBelkum A, Ghaznavi-Rad E. Nosocomial outbreak of extensively and pandrug resistant Acinetobacter baumannii in tertiary hospital in Central part of Iran. Jundishapur J Microbiol 2013; 6:1-5.

32. Shahcheraghi F, Abbasalipour M, Feizabadi M, Ebrahimipour G, Akbari N. Isolation and genetic characterization of metallo-beta-lactamase and carbapenemase producing strains of Acinetobacter baumannii from patients at Tehran hospitals. Iran J Microbiol 2011; 3:68-74.

33. Mugnier PD, Poirel L, Nass T, Nordmann P. Worldwide dissemination of the bla OXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 2010; 16:35-40.

34. Mak JK, Kim MJ, Pham J, Tapsall J, White PA. Antibiotic resistance determinants in nosocomial strains of Multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2009; 63:47-54.

35. Quinteira S, Grosso F, Ramos H, Peixe L. Molecular epidemiology of imipenem resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid mediated OXA-40 from a Portuguese hospital. Antimicrob Agents Chemother 2007; 51:3465-3466.

36. Taherikalani M, Fatolahzadeh B, Emaneini M, Soroush S, Feizabadi MM. Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran hospitals. New Microbiol 2009; 32:265-271.

37. Werneck JS, Picao RC, Girardello R, Cayo R, Marguti V, Dalla-Costa L, et al. Low prevalence of bla OXA-143 in private hospitals in Brazil. Antimicrob Agents Chemother 2011;55:4494-4495.

38. Neves F, Clemente W, Lincopan N, Paiao I, Neves P, Romanelli R, et al. Clinical and microbiological characteristics of OXA-23 and OXA-143 producing Acinetobacter baumannii in ICU patients at a teaching hospital, Brazil. Braz J Infect Dis 2016; 20:556-563.